Immunization, HepB3 in Europe & Central Asia
Europe & Central Asia: Immunization, HepB3 was 90.4% in 2024. ▲ Rising
Immunization, HepB3 in Europe & Central Asia, 1992–2024
Source: World Health Organization (WHO). Measured in % of one-year-old children.
Analysis
In 2024, immunization, hepb3 in Europe & Central Asia stood at 90.4%.
Compared with earlier readings it is down 0.8% on the previous year and up 12.6% over ten years.
Over the whole period, immunization, hepb3 in Europe & Central Asia peaked at 91.7% in 2019 and was at its lowest, 5.0%, in 1992.
That places Europe & Central Asia 9th out of 47 groups with data for 2024, putting it in the top quarter.
The long-run direction has been consistently rising across the 33 years of available data.
Immunization, HepB3 in Europe & Central Asia, year by year
| Year | % of one-year-old children | Change |
|---|---|---|
| 1992 | 5.0% | — |
| 1993 | 6.4% | +27.5% |
| 1994 | 8.6% | +35.2% |
| 1995 | 10.6% | +22.9% |
| 1996 | 18.6% | +75.6% |
| 1997 | 22.1% | +18.7% |
| 1998 | 27.4% | +24.0% |
| 1999 | 29.0% | +5.7% |
| 2000 | 41.7% | +43.8% |
| 2001 | 49.3% | +18.3% |
| 2002 | 62.6% | +27.1% |
| 2003 | 67.3% | +7.5% |
| 2004 | 72.8% | +8.2% |
| 2005 | 74.5% | +2.2% |
| 2006 | 74.9% | +0.6% |
| 2007 | 77.0% | +2.8% |
| 2008 | 76.6% | -0.5% |
| 2009 | 76.9% | +0.5% |
| 2010 | 78.0% | +1.3% |
| 2011 | 78.3% | +0.5% |
| 2012 | 79.6% | +1.7% |
| 2013 | 80.7% | +1.3% |
| 2014 | 80.3% | -0.5% |
| 2015 | 81.1% | +1.1% |
| 2016 | 81.4% | +0.3% |
| 2017 | 83.4% | +2.5% |
| 2018 | 84.2% | +1.0% |
| 2019 | 91.7% | +9.0% |
| 2020 | 90.8% | -1.0% |
| 2021 | 90.8% | -0.0% |
| 2022 | 90.9% | +0.1% |
| 2023 | 91.2% | +0.3% |
| 2024 | 90.4% | -0.8% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 1990s | 16.0% | 5.0% | 29.0% | 8 |
| 2000s | 67.4% | 41.7% | 77.0% | 10 |
| 2010s | 81.9% | 78.0% | 91.7% | 10 |
| 2020s | 90.8% | 90.4% | 91.2% | 5 |
More health data for Europe & Central Asia
- Population ages 35-39, female, annual growth rate -0.1309 % change on previous year (2025)
- Population ages 40-44, female, per capita 0.0352 units per person (2025)
- Population ages 40-44, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 40-44, female, annual growth rate 0.2923 % change on previous year (2025)
- Population ages 35-39, male, per capita 0.0361 units per person (2025)
- Population ages 35-39, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 35-39, male, annual growth rate 0.1122 % change on previous year (2025)
- Population ages 35-39, female, per capita 0.0355 units per person (2025)
- Population ages 35-39, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 25-29, male, per capita 0.0301 units per person (2025)
Frequently asked questions
- What is immunization, hepb3 in Europe & Central Asia?
- Immunization, hepb3 in Europe & Central Asia was 90.4% in 2024, according to World Health Organization (WHO).
- What is the highest immunization, hepb3 recorded in Europe & Central Asia?
- The highest recorded value was 91.7% in 2019.
- What is the lowest immunization, hepb3 recorded in Europe & Central Asia?
- The lowest recorded value was 5.0% in 1992.
- How does Europe & Central Asia rank for immunization, hepb3?
- Europe & Central Asia ranks 9th out of 47 groups with data for 2024.
- Is immunization, hepb3 rising or falling in Europe & Central Asia?
- Over the last ten years it is up 12.6%. The long-run trend across the full record is rising.
- Where does this Europe & Central Asia data come from?
- The figures come from World Health Organization (WHO), published as part of Immunization, HepB3 (% of one-year-old children). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 33 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Child immunization rate, hepatitis B is the percentage of children ages 12-23 months who received hepatitis B vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized after three doses.